JTO Clinical and Research Reports (Apr 2024)

RET Fusion Testing in Patients With NSCLC: The RETING Study

  • Esther Conde, MD, PhD,
  • Susana Hernandez, PhD,
  • Jose Luis Rodriguez Carrillo, MD,
  • Rebeca Martinez, APT,
  • Marta Alonso, APT,
  • Daniel Curto, MD,
  • Beatriz Jimenez, MD,
  • Alejandra Caminoa, MD, PhD,
  • Amparo Benito, MD,
  • Pilar Garrido, MD, PhD,
  • Sergi Clave, PhD,
  • Edurne Arriola, MD, PhD,
  • Isabel Esteban-Rodriguez, MD, PhD,
  • Javier De Castro, MD, PhD,
  • Irene Sansano, MD,
  • Enriqueta Felip, MD, PhD,
  • Federico Rojo, MD, PhD,
  • Manuel Dómine, MD, PhD,
  • Ihab Abdulkader, MD, PhD,
  • Jorge Garcia-Gonzalez, MD,
  • Cristina Teixido, PhD,
  • Noemi Reguart, MD, PhD,
  • Desamparados Compañ, MD, PhD,
  • Amelia Insa, MD,
  • Nuria Mancheño, MD, PhD,
  • Sarai Palanca, MD, PhD,
  • Oscar Juan-Vidal, MD, PhD,
  • Nuria Baixeras, MD,
  • Ernest Nadal, MD, PhD,
  • Maria Cebollero, MD,
  • Antonio Calles, MD,
  • Paloma Martin, MD, PhD,
  • Clara Salas, MD, PhD,
  • Mariano Provencio, MD, PhD,
  • Ignacio Aranda, MD, PhD,
  • Bartomeu Massuti, MD,
  • Laura Lopez-Vilaro, MD,
  • Margarita Majem, MD, PhD,
  • Luis Paz-Ares, MD, PhD,
  • Fernando Lopez-Rios, MD, PhD

Journal volume & issue
Vol. 5, no. 4
p. 100653

Abstract

Read online

Introduction: RET inhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identification of RET fusions remains a difficult challenge. Most guidelines encourage the upfront use of next-generation sequencing (NGS), or alternatively, fluorescence in situ hybridization (FISH) or reverse transcriptase-polymerase chain reaction (RT-PCR) when NGS is not possible or available. Taken together, the suboptimal performance of single-analyte assays to detect RET fusions, although consistent with the notion of encouraging universal NGS, is currently widening some of the clinical practice gaps in the implementation of predictive biomarkers in patients with advanced NSCLC. Methods: This situation prompted us to evaluate several RET assays in a large multicenter cohort of RET fusion–positive NSCLC (n = 38) to obtain real-world data. In addition to RNA-based NGS (the criterion standard method), all positive specimens underwent break-apart RET FISH with two different assays and were also tested by an RT-PCR assay. Results: The most common RET partners were KIF5B (78.9%), followed by CCDC6 (15.8%). The two RET NGS-positive but FISH-negative samples contained a KIF5B(15)-RET(12) fusion. The three RET fusions not identified with RT-PCR were AKAP13(35)-RET(12), KIF5B(24)-RET(9) and KIF5B(24)-RET(11). All three false-negative RT-PCR cases were FISH-positive, exhibited a typical break-apart pattern, and contained a very high number of positive tumor cells with both FISH assays. Signet ring cells, psammoma bodies, and pleomorphic features were frequently observed (in 34.2%, 39.5%, and 39.5% of tumors, respectively). Conclusions: In-depth knowledge of the advantages and disadvantages of the different RET testing methodologies could help clinical and molecular tumor boards implement and maintain sensible algorithms for the rapid and effective detection of RET fusions in patients with NSCLC. The likelihood of RET false-negative results with both FISH and RT-PCR reinforces the need for upfront NGS in patients with NSCLC.

Keywords